silybin has been researched along with Parkinson Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, YB; Gong, JX; Huang, KX; Li, HB; Li, XK; Qu, J; Spencer, S; Tao, QF; Wang, F; Wu, XM; Wu, YH; Yang, LX; Zeng, S; Zhao, Y | 1 |
| Chen, W; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, W; Liu, X; Mizuno, K; Wang, C | 1 |
| Ebadi, SA; Eyvari Brooshghalan, S; Haddadi, R; Mohajjel Nayebi, A; Sabahi, M; Sadeghian, Z | 1 |
| Chen, Y; Fujisaki, H; Hattori, S; Hayashi, T; Ikejima, T; Liu, P; Liu, W; Liu, X; Mizuno, K; Wang, C | 1 |
| Ha, CM; Jang, JH; Jeong, JY; Jin, BK; Jung, UJ; Kim, DW; Kim, HJ; Kim, SR; Leem, E; Moon, GJ; Oh, YS; Shin, M; Shin, WH | 1 |
| Choi, MS; Jeon, MT; Jung, UJ; Kim, SR | 1 |
6 other study(ies) available for silybin and Parkinson Disease
| Article | Year |
|---|---|
Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives.
Topics: Alkenes; Alzheimer Disease; Amides; Animals; Drug Design; Free Radical Scavengers; Humans; Iron Chelating Agents; Lipid Peroxidation; Liver; Male; Models, Molecular; Molecular Conformation; Neurons; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats; Silymarin; Structure-Activity Relationship; Xanthine Oxidase | 2009 |
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Depression; Disease Models, Animal; Humans; Interferon Regulatory Factor-3; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Quality of Life; Silybin | 2021 |
Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Interleukin-6; Molecular Docking Simulation; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Rats; Silybin; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2023 |
Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Mitophagy; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Silybin; Substantia Nigra | 2021 |
Effects of Silibinin Against Prothrombin Kringle-2-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System In Vivo.
Topics: Animals; Dopamine; Dopaminergic Neurons; Humans; Interleukin-1beta; Kringles; Male; Mice, Inbred C57BL; Microglia; Parkinson Disease; Prothrombin; Silybin; Tumor Necrosis Factor-alpha | 2019 |
Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Female; Inflammation; Interleukin-1beta; Microglia; Nerve Degeneration; Neuroprotective Agents; Nitric Oxide Synthase Type II; Parkinson Disease; Rats; Rats, Sprague-Dawley; Silybin; Silymarin; Substantia Nigra; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2014 |